5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
The present invention relates to Compounds having the structure of Formula I: wherein n is an integer from 1 to 5; R 1 is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; R 2 is alkenyl, allcynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, NR 4 R 5 , —NHC(═Y)R 4 , —NHC(═Y)NR 5 R χ , —NHC(═O)OR 4 , —NHSO 2 R 4 , C(═Y)NR 4 R 5 , C(═O)OR 6 [wherein Y is oxygen or sulphur], OR 5 , —O(C═O)NR 4 R 5 , O-acyl, S(O) m R 4 , —SO 2 N(R 4 ) 2 , cyano, amidino or guanidino [wherein R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl and m is an integer 0-2; R 5 is hydrogen or R 4 ; R x is R 4 or —SO 2 N(R 4 ) 2 and R 6 is hydrogen, alkyl, cycloalkyl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl]; R 3 is hydrogen, fluorine, alkyl, cycloalkylalkyl or aralkyl; A is OH, OR 4 , —OC(═O)NR 4 R 5 , O-acyl, NH 2 , NR 4 R 5 , —NHC(═Y)R 4 , —NHC(═Y)NR 5 R x , —NHC(═O)OR 4 , —NHSO 2 R 4 , and to processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over-activation of an matrix metalloproteinase, using the compounds.
1. A compound of Formula Ic:
or racemates, enantiomers, diastereomers, or pharmaceutically acceptable salts thereof wherein:
n is an integer from 1 to 5;
R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy, each of which can be optionally substituted;
R 2a is NR 4 R 5 , —NHC(═Y)R 4 , —NHC(═Y)NR 5 R x , —NHC(═O)OR 4 , —NHSO 2 R 4 , amidino or guanidino;
wherein:
Y is oxygen or sulphur;
R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl;
m is an integer 0-2;
R 5 is hydrogen or R 4 ; or R 4 and R 5 together may optionally form a heterocyclic ring
R x is R 4 or —SO 2 N(R 4 ) 2 ; and
A is OH, OR 4 , —OC(═O)NR 4 R 5 , O-acyl, NH 2 , NR 4 R 5 , —NHC(═Y)R 4 , —NHC(═Y)NR 5 R x , NHC(═O)OR 4 , NHSO 2 R 4 .
2. A compound according to claim 1 which is:
5-Biphenyl-4-yl-3-hydroxy-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid (Compound No. 1),
2-(2-{[(Benzyloxy)carbonyl]amino}ethyl)-5-biphenyl-4-yl-3-hydroxypentanoicacid (Compound No. 11),
5-Biphenyl-4-yl-3-hydroxy-2-{2-[(phenylacetyl)amino]ethyl}pentanoic acid (Compound No. 45),
3-Hydroxy-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]-5-[4′-(trifluoromethyl)biphenyl-4-yl]pentanoic acid (Compound No. 59),
5-(3′,4′-Difluorobiphenyl-4-yl)-3-hydroxy-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid (Compound No. 60),
3-Hydroxy-5-(4′-methoxybiphenyl-4-yl)-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid (Compound No. 64),
5-(4′-Chlorobiphenyl-4-yl)-3-hydroxy-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid (Compound No. 65),
3-Hydroxy-5-[4-(6-methoxypyridin-3-yl)phenyl]-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid (Compound No. 67),
3-Hydroxy-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]-5-[4′-(trifluoromethoxy)biphenyl-4-yl]pentanoic acid (Compound No. 70),
5-(4′-Fluorobiphenyl-4-yl)-3-hydroxy-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid (Compound No. 71),
3-hydroxy-5-(4′-methylbiphenyl-4-yl)-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid (Compound No. 72),
5-(4′-Cyanobiphenyl-4-yl)-3-hydroxy-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid (Compound No. 73),
5-(4′-Ethylbiphenyl-4-yl)-3-hydroxy-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid (Compound No. 76),
5-Biphenyl-4-yl-2-(2-{[(4-fluorophenyl)sulfonyl]amino}ethyl)-3-hydroxypentanoic acid (Compound No. 87),
5-Biphenyl-4-yl-2-(2-{[(3-fluorophenyl)acetyl]amino}ethyl)-3-hydroxypentanoic acid (Compound No. 88),
5-Biphenyl-4-yl-2-{2-[(4-fluorobenzoyl)amino]ethyl}-3-hydroxypentanoic acid (Compound No. 89),
5-Biphenyl-4-yl-2-[2-({[(4-fluorophenyl)amino]carbonyl}amino)ethyl]-3-hydroxypentanoic acid (Compound No. 92),
(2R,3S)-3-Hydroxy-5-[4-(6-methoxypyridin-3-yl)phenyl]-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid (Compound No. 133),
(2S,3R)-3-Hydroxy-5-[4-(6-methoxypyridin-3-yl)phenyl]-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid (Compound No. 134),
(2R,3R)-3-Hydroxy-5-[4-(6-methoxypyridin-3-yl)phenyl]-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid (Compound No. 135), or
(2S,3S)-3-Hydroxy-5-[4-(6-methoxypyridin-3-yl)phenyl]-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid (Compound No. 136)
or racemates, enantiomers, diastereomers, or pharmaceutically acceptable salts thereof.
3. A pharmaceutical composition comprising therapeutically effective amount of a compound according to any one of claims 1 or 2 together with pharmaceutically acceptable carriers, excipients, or diluents.
4. A pharmaceutical composition according to claim 3 further comprising one or more additional active ingredients selected from:
a) anti-inflammatory agents selected from
(i) nonsteroidal anti-inflammatory agents piroxicam, diclofenac, propionic acids, fenamates, pyrazolones, salicylates, PDE-4/p38 MAP Kinase/Cathepsin inhibitors,
(ii) leukotrienes LTC4/LTD4/LTE4/LTB4-Inhibitors, 5-lipoxygenase inhibitors and PAF-receptor antagonists, (iii) Cox-2 inhibitors, (iv) MMP inhibitors, or (v) interleukin-I inhibitors;
b) antihypertensive agents selected from (i) ACE inhibitors, e.g., enalapril, lisinopril, valsartan, telmisartan and quinapril, (ii) angiotensin II receptor antagonists and agonists, e.g., losartan, candesartan, irbesartan, valsartan, and eprosartan, (iii) β-blockers, or (iv) calcium channel blockers; and
c) immunosuppressive agents selected from cyclosporine, azathioprine and methotrexate, anti-inflammatory corticosteroids.
5. A method of treatment of an animal or a human suffering from rheumatoid arthritis which comprises administering to the animal or human an effective amount of a compound according to claim 1 or 2 .
6. A compound according to claim 1 having the structure of formula Ic:
wherein R 1 is heteroaryl or aryl.
7. A compound according to claim 2 which is:
5-Biphenyl-4-yl-3-hydroxy-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid (Compound No. 1), or
2-(2-{[(Benzyloxy)carbonyl]amino}ethyl)-5-biphenyl-4-yl-3-hydroxypentanoicacid (Compound No. 11);
or racemates, enantiomers, diastereomers, or pharmaceutically acceptable salts thereof.
8. A compound according to claim 2 which is 3-Hydroxy-5-[4-(6-methoxypyridin-3-yl)phenyl]-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid or racemates, enantiomers, diastereomers, or pharmaceutically acceptable salts thereof.
9. A compound according to claim 2 which is (2S,3R)-3-Hydroxy-5-[4-(6-methoxypyridin-3-yl)phenyl]-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoic acid or a pharmaceutically acceptable salt thereof.